

Company Number: 648499

Renata Pharmaceuticals (Ireland) Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 June 2025

Renata Pharmaceuticals (Ireland) Limited
CONTENTS

	Page
Statement of Financial Position	3
Notes to the Financial Statements	4 - 5

Renata Pharmaceuticals (Ireland) Limited
STATEMENT OF FINANCIAL POSITION

as at 30 June 2025

	Notes	2025 €	2024 €
Current Assets			
Receivables	4	719,331	1,006,380
Cash and cash equivalents		3,724,741	1,280,279
		<u>4,444,072</u>	<u>2,286,659</u>
Payables: amounts falling due within one year	5	(640,277)	(385,727)
Net Current Assets		<u>3,803,795</u>	<u>1,900,932</u>
Total Assets less Current Liabilities		<u>3,803,795</u>	<u>1,900,932</u>
Equity			
Called up share capital presented as equity		1,000,079	1,000,079
Retained earnings		2,803,716	900,853
Equity attributable to owners of the company		<u>3,803,795</u>	<u>1,900,932</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Renata Pharmaceuticals (Ireland) Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 October 2025 and signed on its behalf by:


 Kaiser Kabir
 Director

Renata Pharmaceuticals (Ireland) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

Renata Pharmaceuticals (Ireland) Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 648499. The registered office of the company is 12 Crowe Street, Dundalk, Co Louth. The principal activity of the company is as Marketing Authorisation Holder for its parent company, Renata Limited (registered in Bangladesh) which facilitates the export and market product in Ireland and other international markets. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Revenue

Revenue comprises the invoice value of goods or services supplied by the company, exclusive of trade discounts and value added tax.

Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other payables

Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

Renata Pharmaceuticals (Ireland) Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 June 2025

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3.	Operating profit	2025	2024
		€	€
	Operating profit is stated after charging:		
	Loss/(profit) on foreign currencies	22,196	-
		<u><u> </u></u>	<u><u> </u></u>
4.	Receivables	2025	2024
		€	€
	Trade receivables	683,193	1,004,198
	Other debtors	100	100
	Taxation	34,286	645
	Prepayments	1,752	1,437
		<u><u>719,331</u></u>	<u><u>1,006,380</u></u>
5.	Payables	2025	2024
	Amounts falling due within one year	€	€
	Trade payables	272,291	170,628
	Taxation	132,712	134,331
	Other creditors	229,431	79,784
	Accruals	5,843	984
		<u><u>640,277</u></u>	<u><u>385,727</u></u>
6.	Income Statement		
		2025	2024
		€	€
	At 1 July 2024	900,853	(47,638)
	Profit for the financial year	1,902,863	948,491
		<u><u>2,803,716</u></u>	<u><u>900,853</u></u>
7.	Parent company		
	The company regards Renata Limited as its parent company.		
8.	Controlling interest		
	The company regards Renata Limited as the ultimate parent company, a company registered in Bangladesh.		